Ascendis Pharma ASND
DenmarkHealthcare · BiotechnologyUSD
305.91 USD (+33.9%)
20 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Ascendis Pharma is a Danish biopharmaceutical company that develops innovative precision therapies for endocrine and rare diseases, using its prolonged-release technology platform (TransCon) to improve the efficacy and convenience of treatments.
Key points
from its scores- ✓Strong growth10.0
- ✓Very solid balance sheet9.4
- ✕Little or no dividend1.5
- ✕Demanding valuation3.4
- ✕Unfavourable risk and backdrop4.7
AI analysis
bottom line, main risk, context and newsHold, given the strong growth and solid financial health, but with caution due to the demanding valuation and dependence on regulatory approvals.
Ascendis Pharma shows a solid financial profile with net cash (ND/EBITDA -1.37), gross margins of 91.3%, and revenue growth of 114.7%, although its valuation is demanding (EV/EBITDA 49.55) and free cash flow conversion is weak (4.85). The main risk is regulatory, inherent to its sector.
Regulatory risk: dependence on FDA and EMA approvals for its therapies, along with the possibility of clinical trial setbacks or reimbursement decisions, could significantly impact future revenues.
Context and risks
Ascendis Pharma is a Danish biopharmaceutical company with a global business model and no material exposure to interest rates, commodities, or shipping routes. Its main contextual risk is regulatory, inherent to the biotech sector: the approval and commercialization of its therapies depend on drug agencies (FDA, EMA), and any setback in clinical trials or reimbursement decisions could affect future revenues.
Is Ascendis Pharma stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 104% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 17.5 | 26.7 | −35% |
| EV / EBITDA | 49.6 | 14.5 | +242% |
| Price / sales | 12.8 | 3.4 | +275% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.4 out of 10 (median for Healthcare: 4.7).
Average analyst target: 305.91 USD, +33.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.6 (sector 5.5), Growth 10.0 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 17.5
- Forward P/E
- 21.1
- EV / EBITDA
- 49.6
- Price / sales
- 12.8
- Market cap
- 15.0B USD
- Enterprise value
- 13.1B EUR
Profitability
- ROE
- 118.8%
- ROA
- 9.6%
- Gross margin
- 91.3%
- Operating margin
- 65.0%
- Net margin
- 70.8%
- Free cash flow
- 12.8M EUR
- FCF yield
- 0.1%
- Cash conversion
- 5%
Solvency
- Total debt
- 450.1M EUR
- Net debt
- −362.2M EUR
- Cash
- 812.3M EUR
- EBITDA
- 263.5M EUR
- Net debt / EBITDA
- −1.37
- Debt / equity
- 31.33
- Current ratio
- 2.99
- Quick ratio
- 2.23
Growth
- Revenue growth
- +114.7%
- EPS (TTM)
- 13.05 USD
- EPS (forward)
- 10.82 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Analyst consensus
- Strong buy (20)
- Target price
- 305.91 USD
- 52-week range
- 186.05 – 282.15
Recent news
All ASND news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Ascendis Pharma
Is Ascendis Pharma stock cheap or expensive?
On P/E and EV / EBITDA, it trades 104% above the Healthcare median on average. Valuation score: 3.4 out of 10 (median for Healthcare: 4.7). Average analyst target: 305.91 USD, +33.9% versus the price. This is not investment advice.
What score does Ascendis Pharma get on MeridIAn Screener?
It scores 6.1 out of 10, rank 870 of 2,130 (better than 55% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Ascendis Pharma's P/E ratio?
Its P/E is 17.5: the share price equals 17.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 21.1.
How much is Ascendis Pharma worth on the stock market?
Its market capitalisation is 15.0B USD and its enterprise value, debt included, is 13.1B USD.
How much debt does Ascendis Pharma have?
It has more cash than debt: net cash of 362.2M EUR.
Does Ascendis Pharma pay a dividend?
It pays no dividend, or almost none.
How has Ascendis Pharma stock performed over the last year?
It has risen 9.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 186.05 and 282.15 USD. Past performance does not guarantee future results.
What do analysts think of Ascendis Pharma?
20 analysts cover it; their average recommendation is “Strong buy” and their average target is 305.91 USD (+33.9% versus the price). It is an estimate, not market data.